Yatiri Bio Investor Day

Yatiri Bio is at a compelling value inflection point, having generated unprecedented evidence that its platform can accurately predict patient outcomes for a known therapeutic. The company is advancing an investigator-initiated oncology trial at Fred Hutch designed to generate early clinical and biomarker validation, while simultaneously finalizing the in-licensing of a differentiated, Phase 2 clinical-stage therapeutic asset. This private investor briefing will highlight a focused, execution-driven near-term strategy, clearly defined value-creating milestones, and how targeted capital will accelerate initiation of the Fred Hutch trial and position the company for rapid transition into a pivotal Phase 2 program. We look forward to engaging with potential investors around a clear plan for creating meaningful near-term value and accelerating the company’s next phase of growth

Know what’s Happening Next — before everyone else does.

Get App

Host or Publisher Yatiri Bio